Additionally, IL-22, which is functionally associated with IL-23R signaling, has been implicated in promoting Sorafenib resistance in HCC through STAT3 activation, leading to enhanced tumor cell survival and decreased apoptosis. This evidence concerns the gene IL22 and hepatocellular carcinoma.